Trial Profile
A Phase I, 2-Panel, Open-Label Study in Healthy Subjects to Investigate the Pharmacokinetic Interaction Between TMC435 and the HMG-CoA Reductase Inhibitors Atorvastatin and Simvastatin
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Nov 2012
Price :
$35
*
At a glance
- Drugs Simeprevir (Primary) ; Atorvastatin; Simvastatin
- Indications Cardiovascular disorders; Cystic fibrosis; Diabetic cardiomyopathy; Diabetic nephropathies; Heart failure; Hepatitis C; Hypercholesterolaemia; Hyperlipoproteinaemia; Hyperlipoproteinaemia type II; Hyperlipoproteinaemia type III; Hypertriglyceridaemia; Low HDL cholesterol
- Focus Pharmacokinetics
- 24 Sep 2012 New trial record